source
- Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warningSanofi has warned that supplies of two medicines used to treat Pompe disease are running low. The company notified patient groups and physicians in the United States and Europe that the shortage af…
- Replimune secures FDA accelerated approval for melanoma therapy TudriqevReplimune announced that the FDA has granted accelerated approval to its melanoma therapy RP1, marketed as Tudriqev, after two earlier rejections and a third expedited review. The decision reflects…